Clinical trials: Injector
Healthy Subjects
Autoinjector Device Assessment Study
Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.
- Trial name
- BCB119 (NCT02349802)
- Testing
- Auto-injector with exenatide suspension, Syringe with exenatide suspension
- Where
- 2 sites in United States
- Volunteers
- 3,052 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteer
Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults
The Goal of these study is to assess the comparative pharmacokinetics of Test Product (A): TPI-120 Injection 6 mg/0.6 mL solution in a single dose pre-filled autoinjector, manufactured by Kashiv Biosciences LLC, USA with…
- Trial name
- NCT07416955
- Testing
- TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Kashiv BioSciences, LLC
Overweight, Obesity
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity.
- Trial name
- NCT04012255
- Testing
- Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen)
- Where
- 2 sites in Germany
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
Healthy
Safety and Efficacy of EZ-Ject Injector a Pain-Free Subcutaneous Automatic Injection in Healthy Volunteers
Subcutaneous injections are a widely used method for drug delivery. One of its major drawbacks is the pain inflicted during the process.
- Trial name
- NCT00684333
- Testing
- painless subcutaneous injection by EZ-Ject Injector
- Where
- Israel
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sindolor
Healthy Volunteers
A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
The purpose of the study is to evaluate the pharmakokinetics (PK), safety, tolerability, and immunogenicity of bimekizumab (BKZ) when administered subcutaneously (sc) via 3 different BKZ delivery devices in healthy participants.
- Trial name
- NCT03707717
- Testing
- Bimekizumab
- Where
- 2 sites in United States, Germany
- Volunteers
- 189 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Healthy Volunteers
A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
The primary purpose of this study is to demonstrate the bioequivalence (BE) of a single subcutaneous (SC) dose of lecanemab via vial and AI in healthy participants.
- Trial name
- NCT05533801
- Testing
- Lecanemab
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Growth Disorders
Saizen® E-Device User Trial
The aim of the study is to evaluate the E-Device performances and handling on the use in common practice, by collecting the impressions of patients, nurses and the investigator on the graphic interface, the instructions manual…
- Trial name
- NCT00450190
- Testing
- Saizen® E-Device
- Volunteers
- 20 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Rheumatoid Arthritis
Preference of Rheumatoid Arthritis (RA) Patients of Enbrel® (Etanercept) Auto-Injector Versus Enbrel® Pre-Filled Syringes
The purpose of this study is to determine the preference of RA patients for the new Enbrel® (etanercept) pre-filled syringe in patients who are already taking Enbrel®.
- Trial name
- NCT00094341
- Testing
- Etanercept
- Volunteers
- 215 people
- Sponsor
- Amgen
Healthy Participants
Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe
The purpose of this study is to develop an auto-injector (AI) device for the BMS-986036 subcutaneous formulation that can be self-administered conveniently by participants.
- Trial name
- NCT04493567
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic, Hepatitis C
Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED)
The objective of the study is to assess the safety and efficacy of PegIntron injector and Rebetol administered to participants with chronic hepatitis C.
- Trial name
- NCT00727311
- Testing
- PegIntron (peginterferon alfa-2b; SCH 54031) injector, Rebetol (ribavirin; SCH 18908)
- Volunteers
- 2,302 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Macular Edema
Everads Injector in Suprachoroidal Administration of TA Suspension, for Treatment of Patients With DME
This is an open-label pilot device study. The aim of the study is to evaluate the safety and performance of Everads Injector following single injection of suspension approved for ocular use into the suprachoroidal space.
- Trial name
- NCT06314217
- Testing
- Everads Injector
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Everads Therapy
Psoriatic Arthritis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis
The purpose of the study is to evaluate for each self-injecting device presentation the ability of subjects with psoriatic arthritis (PsA) to safely and effectively self-inject bimekizumab at study start and 4 weeks after…
- Trial name
- NCT04109976
- Testing
- Bimekizumab
- Where
- 47 sites in United States, Czechia and 4 more
- Volunteers
- 214 people
- Sponsor
- UCB Biopharma SRL
Generalized Myasthenia Gravis
A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.
- Trial name
- NCT06471361
- Testing
- Zilucoplan
- Where
- 11 sites in United States, Poland and 1 more
- Volunteers
- 31 people
- Sponsor
- UCB Biopharma SRL
Influenza, Human
A Pilot Study to Evaluate the Safety and Immunogenicity of Low Dose Flu Vaccines
The purpose of this study is to determine whether low dose flu vaccines delivered with microneedles into the skin (intradermally) are effective.
- Trial name
- NANOVAX (NCT00558649)
- Testing
- Flu Vaccine (FLUARIX®)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- NanoPass Technologies Ltd
Healthy Volunteers
A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)
This is a randomized, 2-part, 2-arm, open-label, parallel-group, multi-center study to compare the PK of etrolizumab administered subcutaneously by an AI (test device) or a PFS-NSD (reference device) in healthy participants.
- Trial name
- NCT02996019
- Testing
- Etrolizumab, Auto-Injector (AI), Prefilled Syringe With Needle Safety Device (PFS-NSD)
- Where
- 4 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Overweight, Obesity
A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
The study will look at how two different forms of semaglutide reach and stay in the blood after injection. None of the two forms of semaglutide have been approved by the authorities to treat obesity, but it has been approved as a…
- Trial name
- NCT04187300
- Testing
- Semaglutide
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants
This study will assess the pharmacokinetics and relative Bioavailability of risankizumab following subcutaneous administration with an on-body injector relative to a prefilled syringe
- Trial name
- NCT07007091
- Testing
- Risankizumab
- Where
- 4 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- AbbVie
Multiple Sclerosis, Relapsing-Remitting
Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction
The primary objective of this study is to assess adherence and persistence to BETASERON therapy in patients who are using the BETACONNECT auto-injector device (BETACONNECT device).
- Trial name
- NCT02652091
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046), BETACONNECT device
- Where
- 23 sites in United States
- Volunteers
- 146 people
- Sponsor
- Bayer
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis
Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS
The primary objective of this study is to demonstrate equivalence of the pharmacokinetic (PK) profile of MSB11022 administered by either an auto-injector (AI) or a pre-filled syringe (PFS) as single subcutaneous (s.c.) injection…
- Conditions
- Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT04018599
- Testing
- 40 mg MSB11022
- Where
- 2 sites in United States
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Growth Hormone Deficiency, Turner Syndrome
Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
This is an international, multicenter study involving children treated with Saizen®, a growth hormone, who will be trained to use easypod, a new electronic injector and will complete a questionnaire after 12 week of use.
- Conditions
- Growth Hormone Deficiency, Turner Syndrome, Chronic Renal Failure, Small for Gestational Age
- Trial name
- NCT00738205
- Volunteers
- 834 people
- Sponsor
- Merck KGaA, Darmstadt, Germany